Baxalta opens R&D Global Innovation Centre
4 December 2015 | By Victoria White
By the end of 2015, Baxalta says it expects to employ approximately 500 individuals at the Global Innovation Centre...
List view / Grid view
News
Nanobombs – the future of cancer drug delivery?
3 December 2015 | By Victoria White
Researchers say nanobombs might overcome a biological barrier that has blocked development of agents that work by altering the expression of genes in cancer cells...
Morphotek enters collaboration to investigate CA125 tumour antigen
3 December 2015 | By Victoria White
Morphotek has teamed up with UW-Madison to investigate the immunosuppressive effects of CA125 on farletuzumab...
Scientists engineer potential treatment for pertussis
3 December 2015 | By Victoria White
Preclinical testing demonstrated that the new antibodies work as a prophylaxis to provide short-term immunity and as a treatment to accelerate recovery...
New class of inhibitory compounds aid melanoma treatments
3 December 2015 | By Victoria White
Using cell cultures of melanoma, researchers showed that these acid ceramidase inhibitors make melanoma cells more prone to be killed...
Oncology therapeutic pipeline boasts over 6,000 products
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
Boehringer Ingelheim and MD Anderson in pancreatic cancer collaboration
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
MabVax files IND with the FDA for HuMab 5B1
2 December 2015 | By Victoria White
In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers...
Scientists significantly reduce errors in CRISPR-Cas9 genome editing system
1 December 2015 | By Victoria White
The team from the Broad Institute and the McGovern Institute for Brain Research found that mutations in three amino acids dramatically reduced “off-target” cuts...
Adaptimmune and Universal Cells in T-cell therapy collaboration
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
Amcure awarded BMBF research grant to advance lead candidate
1 December 2015 | By Victoria White
Amcure will use the €1.9 million grant to support the initiation of first-in-man studies for the company's lead candidate for the treatment of epithelial tumours...
Daiichi Sankyo to close research subsidiary U3 Pharma
1 December 2015 | By Victoria White
U3 Pharma is a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer...
CFTR interacts with the wrong partners in cystic fibrosis
30 November 2015 | By Victoria White
By removing these interactions, the researchers partially restored the protein’s normal function. The findings suggest that therapies could one day treat the root cause of cystic fibrosis, not just the symptoms...
Functional human hepatocytes grown in the lab
30 November 2015 | By Victoria White
This groundbreaking development could help advance a variety of liver-related research and applications...
Heptares and Pfizer to focus on GPCR targets
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...